Abstract
Risk reduction and the attainment of good outcomes in contemporary cataract surgery depend in part on patient compliance with a postoperative regimen of topical eye drops. Topical drops are expensive and challenging to instill properly for patients. The consequences of noncompliance or poor compliance can be significant for the patient (in the case of a complication) and for society (in the case of development of antibiotic resistance). For all of these reasons, new approaches that reduce the need for topical therapy are beginning to emerge, including intracameral injection, sustained or slow-release drug delivery mechanisms, and the recently introduced “Dropless cataract surgery,” which involves intravitreal injection of single-use, compounded combination of antibiotics and corticosteroids. This paper is a review of the rationale for reducing topical therapy in cataract surgery prophylaxis, and what is known to date about the efficacy and safety of the dropless approach.
Keywords: Cataract surgery, antibiotic prophylaxis, endophthalmitis, intracameral, intravitreal, corticosteroid, compliance, transzonular injection.
Current Pharmaceutical Design
Title:Dropless Cataract Surgery: An Overview
Volume: 23 Issue: 4
Author(s): Richard L. Lindstrom, M. Stewart Galloway, Andrzej Grzybowski and Jeffrey T. Liegner
Affiliation:
Keywords: Cataract surgery, antibiotic prophylaxis, endophthalmitis, intracameral, intravitreal, corticosteroid, compliance, transzonular injection.
Abstract: Risk reduction and the attainment of good outcomes in contemporary cataract surgery depend in part on patient compliance with a postoperative regimen of topical eye drops. Topical drops are expensive and challenging to instill properly for patients. The consequences of noncompliance or poor compliance can be significant for the patient (in the case of a complication) and for society (in the case of development of antibiotic resistance). For all of these reasons, new approaches that reduce the need for topical therapy are beginning to emerge, including intracameral injection, sustained or slow-release drug delivery mechanisms, and the recently introduced “Dropless cataract surgery,” which involves intravitreal injection of single-use, compounded combination of antibiotics and corticosteroids. This paper is a review of the rationale for reducing topical therapy in cataract surgery prophylaxis, and what is known to date about the efficacy and safety of the dropless approach.
Export Options
About this article
Cite this article as:
Lindstrom L. Richard, Galloway Stewart M., Grzybowski Andrzej and Liegner T. Jeffrey, Dropless Cataract Surgery: An Overview, Current Pharmaceutical Design 2017; 23 (4) . https://dx.doi.org/10.2174/1381612822666161129150628
DOI https://dx.doi.org/10.2174/1381612822666161129150628 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo- Controlled Study
Current Alzheimer Research A Key Role for Altered Dendritic Cell Functioning in the Impaired Immunity Seen in Aged Individuals
Current Immunology Reviews (Discontinued) Phytochemistry and Pharmacological Update on Tetraterpenoids
The Natural Products Journal Pharmacological Inhibition of Interleukin-8 (CXCL8) as a New Approach for the Prevention and Treatment of Several Human Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Osteoarthritis - An Update
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Xuesaitong May Protect Against Ischemic Stroke by Modulating Microglial Phenotypes and Inhibiting Neuronal Cell Apoptosis via the STAT3 Signaling Pathway
CNS & Neurological Disorders - Drug Targets Cannabinoids and Schizophrenia: Therapeutic Prospects
Current Pharmaceutical Design Neuroprotective Strategies in Glaucoma
Current Pharmaceutical Design Targeted Drug Delivery for Breast Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Replicative Oncolytic Herpes Simplex Viruses in Combination Cancer Therapies
Current Gene Therapy Phase II Drug Metabolism and Individualized Drug Therapy: A Focus on Functional Genetic Variation in UDP-Glucuronosyltransferases
Current Pharmacogenomics and Personalized Medicine Neutrophil Activation Induced by Plant Lectins: Modulation of Inflammatory Processes
Inflammation & Allergy - Drug Targets (Discontinued) Role of the heme oxygenase-adiponectin-atrial natriuretic peptide axis in renal function
Current Pharmaceutical Design Microglia and Astrocytes in Alzheimer's Disease: Implications for Therapy
Current Neuropharmacology Electroporation: An Avenue for Transdermal Drug Delivery
Current Drug Delivery Potential Biomarkers for Depression Associated with Coronary Artery Disease: A Critical Review
Current Molecular Medicine Drugs and Rhabdomyolysis: From Liver to Kidney
Current Vascular Pharmacology Xenobiotic-Metabolizing Enzymes in Human Lung
Current Drug Metabolism Nuclear Factor Kappa B: A Potential Target for Anti-HIV Chemotherapy
Current Medicinal Chemistry The Impact of Asymmetric Dimethylarginine (ADAMA), the Endogenous Nitric Oxide (NO) Synthase Inhibitor, to the Pathogenesis of Gastric Mucosal Damage
Current Pharmaceutical Design